For six years, Dell has joined TGen at the bedside of pediatric cancer patients. The key to treating them lies somewhere in the vast number of data points that make up the human genome. Dell Technologies has invested over $40 million in funding, technology, and expertise to help TGen find those answers.
With the right data, TGen doctors can prescribe the right treatments, saving their patients’ little bodies from lots of ineffective drugs and harsh side effects. Our high-performance computing delivers that data at incredible speed, so TGen doctors can make treatment decisions in hours instead of weeks.
That’s not just better for patients. It’s also a huge relief for families to know what the health issue is, and that their child is receiving the best possible treatment from day one.